eISSN 2329-0358

Logo


Welcome to the Annals of Transplantation

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more


Published: 2016-08-25

4-Factor Prothrombin Complex Concentrate (PCC4, Kcentra®) Protocol Reduces Blood Requirements for Heart Transplantation: A Novel Protocol

Jacqueline Pratt Cleary, Laura Hodge, Brittany Palmer, Christopher J. Barreiro, Amanda Ingemi

(Albany College of Pharmacy and Health Sciences, Albany, NY, USA)

Ann Transplant 2016; 21:531-537

DOI: 10.12659/AOT.898496


BACKGROUND: All patients with a ventricular assist device (VAD) awaiting heart transplantation are anticoagulated with warfarin to prevent thromboembolism. The use of 4 factor prothrombin complex concentrate (PCC4, Kcentra®) for anticoagulation reversal prior to surgery may include benefits such as quicker reversal, longer duration of action, and a reduction in total volume of blood products used compared to other reversal practices. The study objective is to evaluate benefits of using an anticoagulation reversal protocol featuring PCC4, over standard of care in heart transplant patients requiring anticoagulation.
MATERIAL AND METHODS: This is a single center, combined retrospective and prospective, time-matched cohort study compared 12 patients transplanted pre-protocol and 11 patients transplanted post-protocol. The primary outcome was the total volume of blood and blood products used. Secondary outcomes included length of hospital and ICU stay, safety and adverse events, primary chest closure, and a cost comparison.
RESULTS: The PCC4 reversal protocol showed a significant reduction in total blood volume received with an overall decrease of 1.76L (4.20L pre-protocol, 2.45L post-protocol, P=0.037), total units of blood products infused (20 units pre, 12 units post, P=0.033), and units of packed red blood cells (7 units pre, 3 units post, P=0.033). All heart transplant recipients were listed Status 1A with the primary indication being infection (n=12; 52%). Baseline characteristics, survival, and cost were not different between the ... read more

Keywords: Anticoagulants, Heart Transplantation, Heart-Assist Devices



Related Articles (0)

Coming Soon...

Published: 2016-08-23

Exchange of Partial Liver Transplantation Between Children with Different Non-Cirrhotic Metabolic Liver D...


Cheng-Yen Chen, Chinsu Liu, Niang-Cheng Lin, Hsin-Lin Tsai, Che-Chuan Loong, Cheng-Yuan Hsia

Ann Transplant 2016; 21:525-530

DOI: 10.12659/AOT.898677

Published: 2016-08-18

Public Opinion on Organ Donation After Death and Its Influence on Attitudes Toward Organ Donation


Luo Aijing, Xie Wenzhao, Wei Wei, Wan Qiquan, Deng Xuantong

Ann Transplant 2016; 21:516-524

DOI: 10.12659/AOT.899268